Marathon Digital Holdings Inc vs TG Therapeutics Inc — how do they compare? Marathon Digital Holdings Inc trades at $12.25 (market cap $4.45B), while TG Therapeutics Inc trades at $54.04 (market cap $8.26B). The key difference: TG Therapeutics Inc is the larger of the two by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Marathon Digital Holdings Inc nearer its low. Which is the better fit depends on your goals.
| MARA | TGTX | |
|---|---|---|
Market Cap | $4.45B | $8.26B |
Sector | Technology | Health |
52-Week High | $22.84 | $59.06 |
52-Week Low | $6.73 | $26.39 |
Enterprise Value | $6.40B | $8.50B |
Signals from Pluang's Aura AI — not financial advice
Marathon Digital Holdings (MARA) trades at $11.67, up 9.17% today, amid a strategic pivot from Bitcoin mining to AI infrastructure. Despite recent earnings misses and negative profitability metrics, the stock shows technical support near $10-11 levels. The company's acquisition of a 1,200-acre Texas site with 2 GW power capacity represents a significant expansion opportunity, though cash flow remains negative from operations.
MARA presents a high-risk opportunity with Wall Street analysts maintaining a 50% buy rating and $16.90 consensus target. The AI pivot could drive long-term growth, but investors face substantial execution risks amid persistent losses and negative cash flow. Near-term performance depends on successful business transformation and improved profitability.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Marathon Digital Holdings, Inc. is one of the largest publicly traded Bitcoin mining companies in North America. The company focuses on building and operating large-scale, cost-efficient Bitcoin mining facilities. Marathon's strategy centers on increasing its mining hash rate and using sustainable energy sources to expand its Bitcoin production. The company's performance is closely tied to the price of Bitcoin and the overall health of the digital asset mining industry.
Read more on MARA →TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →